Devyser wins tender for thalassemia in Italy

Devyser was awarded a tender for its NGS product Devyser Thalassemia, which is used for screening and confirmation of thalassemia, a hereditary blood disorder. The tender with Instituto Giannina Gaslini in Genova is valid for a period of 24 months. The indicative order value of the tender is estimated to be approximately 3.5 million SEK.

“The tender strengthens our already strong position in the Italian market, and I am very proud of the entire team who made this happen,” says CEO Fredrik Alpsten. "This tender is another confirmation of the competitiveness and high quality of Devyser Thalassemia."

Thalassemia is a hereditary blood disorder associated with mild to severe anemia, bone problems, and slow growth in children. An estimated 5.2 percent of people carry a thalassemia-causing genetic mutation. Devyser Thalassemia, an end-to-end solution for screening and confirmation of thalassemia, gives users a comprehensive genetic profile for thalassemia gene clusters with a fast turnaround time and minimal hands-on time. The NGS workflow is suitable for any lab, whether running advanced genetic testing or large-scale mutation screening.

Datum 2024-05-27, kl 08:00
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!